Tolbutamide
From Wikipedia, the free encyclopedia
 |
|
|
Tolbutamide
|
|
| Systematic (IUPAC) name | |
| 3-butyl-1-(4-methylphenyl)sulfonyl-urea | |
| Identifiers | |
| CAS number | 64-77-7 |
| ATC code | A10BB03 V04CA01 |
| PubChem | 5505 |
| DrugBank | APRD00267 |
| Chemical data | |
| Formula | C12H18N2O3S |
| Mol. weight | 270.349 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 96% |
| Metabolism | Hepatic (CYP2C19-mediated) |
| Half life | 4.5 to 6.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral (tablet) |
Tolbutamide is a first generation sulfonylurea oral hypoglycemic drug sold under the brand name Orinase. This drug may be used in the management of type II diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas. Since the pancreas must synthesize insulin in order for this drug to work, it is not effective in the management of type I diabetes. It is not routinely used due to a higher incidence of adverse effects compared to newer second generation sulfonylureas, such as glyburide.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
